FAQ

idrabiotaparinux

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
02420082016

Related topics

Related topics

3 relations

Broader (2)

BiotinOligosaccharides
analogs & derivatives

Related mentions per year

Related mentions per year

1940-2018
19401960198020002020
idrabiotaparinux
Oligosaccharides
Biotin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
BACKGROUND Idrabiotaparinux, a long-acting inhibitor of factor Xa, was shown to be effective in the treatment of patients with… (More)
Is this relevant?
2013
2013
Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
AIM To assess the bioequipotency of equimolar doses of idraparinux (2.5 mg) and idrabiotaparinux (3.0 mg). METHOD In a phase I… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Review
2013
Review
2013
Idraparinux or Idrabiotaparinux for Long-Term Venous Thromboembolism Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
BACKGROUND Venous thromboembolism (VTE) is a prevalent disease with potential serious consequences. Idraparinux and… (More)
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority…
BACKGROUND Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2011
2011
Anticoagulation therapy: Idrabiotaparinux noninferior to warfarin for long-term treatment of pulmonary embolism
as a once-weekly subcutaneous injection. Another benefit of idrabiotaparinux is that it contains a biotin moiety, which allows… (More)
Is this relevant?
2010
2010
Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
BACKGROUND Idraparinux is an inhibitor of activated factor X (FXa) with a long half-life allowing once-weekly dosing… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Idraparinux and idrabiotaparinux.
Idraparinux is a polymethylated synthetic pentasaccharide that binds to antithrombin with high affinity. Idrabiotaparinux is a… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2010
2010
Newer antithrombotic drugs
Thromboembolic disorders are one of the disorders for which we are still on the look out for a safe and efficient drug. Despite… (More)
Is this relevant?
2009
2009
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.
BACKGROUND Idraparinux, a long-acting synthetic pentasaccharide, is a specific antithrombin-dependent inhibitor of activated… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2009
Review
2009
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. It was designed for weekly, rather than… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?